Alteogen Creating a New Future

Alteogen is a leading bio venture company whose portfolio includes next-generation bio-better, with improved efficacy in comparison with existing biologics, and biosimilars that demonstrate “comparability” to the approved biologics with proprietary platform technology.

  • NexP™ Fusion TechnologyNext generation persistent technology which utilizes human A1AT (ALPHA-1 Anti-trypsin) protein, abundant in human blood, as the protein carrier which increases half-life of biomedicines
  • NexMab™ ADC TechnologyProprietary Antibody-Drug Conjugate (ADC) technology with superior stability, efficacy, and economical feasibility

  • Hybrozyme Technology – Novel human hyaluronidase PH20 variant for subcutaneous (SC) drug delivery conversion from IV injection with improved thermal stability

  • Biosimilars – Differentiated biosimilars with proprietary technology

Alteogen is preparing better future by focusing on the three cutting edge areas, Hybrozyme™, Long-acting bio-better, proprietary antibody-drug conjugate (ADC), and monoclonal antibody biosimilars.